Save the date for the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Connect with your colleagues for an unmatched educational experience featuring exceptional sessions by leading rheumatology experts. The ACR/ARHP Annual Meeting is your gateway to global rheumatology education. With more than 450 sessions—including The Great Debate—the meeting provides boundless opportunities for professional development,…
Search results for: cardiovascular disease
HCQ Debate: Should Dose Be No More Than 5 mg/kg in All SLE Patients?
Multiple studies show that hydroxychloroquine (HCQ) has many benefits in systemic lupus erythematosus (SLE), including cardiovascular benefits, such as reducing coronary artery and thrombosis risks. HCQ can prevent disease flares, including in renal and central nervous system lupus, and is the only drug shown to prolong survival in lupus. However, guidelines released in 2016 by…
Sessions to Check Out During the 2018 ACR/ARHP Annual Meeting
With more than 450 sessions, the 2018 ACR/ARHP Annual Meeting, is your gateway to global rheumatology education. Here is a preview of a few sessions attendees can look forward to…
A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study
“You have systemic sclerosis,” says the physician. Other somber words patients may hear the day they learn their diagnosis include, “rare, chronic, no treatment.” But a ray of hope could soon enter those exam rooms thanks to research conducted by a team from the UK. Rizgar A. Mageed, PhD, FRCP, FRCPath, is professor of experimental…
5 Ways to Improve Your Collaboration with Orthopedic Surgeons
Rheumatologists and orthopedic surgeons must frequently collaborate to provide optimal patient care. Sometimes, they may even work at the same practice and form a care team for easy collaboration. Still, patient management from both specialties can be challenging, and specialists from both sides can learn from each other. How Crossover Starts Rheumatologists and orthopedic surgeons…
Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis
For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….
Upadacitinib Promising for RA Patients
Upadacitinib proved safe and effective in RA patients who had inadequate responses to conventional disease-modifying anti-rheumatic drugs…
Lupus & Cognitive Dysfunction: No Apparent Link to Inflammation
Does cognitive dysfunction in SLE patients result from persistent inflammation characterized by ongoing disease activity? Recent research examining this question found no inflammatory mechanism associated with cognitive dysfunction in this patient population, underscoring previous research findings…
Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App
CHICAGO—As good an option as hydroxychloroquine (HCQ) is for many patients with rheumatic diseases, such as rheumatoid arthritis and especially lupus, safety must be an important consideration, an expert said at this April’s ACR State-of-the-Art Clinical Symposium. The use of the antimalarial has become a controversial subject, with clinicians trying to balance the drug’s disease-modifying…
When & How to Talk to Your Patients About Their Gender & Sex
How do you ask a new patient about sex and gender—or know which pronoun to use? Keep the conversation straightforward and respectful to put everyone at ease, says Morgan Orndorff, a transgender man who works as an administrator at a major academic medical center. “Everyone is a little different in terms of their sensitivity level”…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 59
- Next Page »